High glucose and renin release: the role of succinate and GPR91

János Peti-Peterdi1

  • 1Departments of Physiology and Biophysics, and Medicine, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, California, USA. petipete@usc.edu

Kidney International
|September 24, 2010
PubMed

Insights

The GPR91 receptor, activated by succinate, plays a key role in early diabetes, triggering renin release and kidney injury. This discovery shifts focus to the distal nephron

Area of Science:

  • Nephrology
  • Endocrinology
  • Metabolic Research

Background:

  • Diabetes mellitus is a leading cause of end-stage renal disease.
  • Intrarenal renin-angiotensin system (RAS) activation is a hallmark of diabetic kidney pathology, but its mechanism is unclear.
  • The novel metabolic receptor GPR91 has been identified within the kidney.

Purpose of the Study:

  • To investigate the role of the GPR91 receptor in the pathogenesis of diabetic nephropathy (DN).
  • To elucidate the mechanism of RAS activation in early diabetes.
  • To explore the function of GPR91 in triggering renin release and renal tissue injury.

Main Methods:

  • Investigated intrarenal GPR91 localization and function in diabetes.
  • Examined GPR91's role in renin release from vascular and tubular sites.
  • Assessed MAP kinase activation in the distal nephron-collecting duct.

Main Results:

  • GPR91 is localized within the kidney and mediates renin release in early diabetes.
  • GPR91 activation triggers MAP kinase signaling in the distal nephron-collecting duct, contributing to DN.
  • Succinate accumulation and GPR91 signaling are early responses to hyperglycemia, promoting renal injury.

Conclusions:

  • GPR91 is a crucial sensor of hyperglycemia and a mediator of early diabetic kidney injury.
  • The distal nephron-collecting duct, expressing high GPR91 levels, plays an active role in DN pathogenesis.
  • This challenges the traditional glomerulus-centric view of diabetic nephropathy.

Related Concept Videos

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...